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license (http://creativeare abnormal in Alzheimer’s disease (AD) have not been assessed in mild cognitive impairment (MCI).
Methods: Participants (n 5 20 per group) had either MCI converting to dementia within 3 years
(MCIC), MCI remaining stable over 3 years (MCIS), Alzheimer’s disease, or were controls. CPs
of ADEs isolated from plasmas by anti-human glutamine aspartate transporter antibody absorption
were quantified by ELISAs.
Results: ADE levels of C1q and C4b of the classical pathway, factor D and fragment Bb of the alter-
native pathway, and C5b, C3b, and C5b-C9 of both pathways were significantly higher in patients
with MCIC than those with MCIS. ADE levels of inhibitory CPs decay-accelerating factor, CD46,
CD59, and type 1 complement receptor were significantly lower in patients with MCIC than those
with MCIS.
Discussion: ADE CPs are components of neurotoxic neuroinflammation that may be predictive bio-
markers of MCI conversion to Alzheimer’s disease.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Neuroinflammation; Neurodegeneration; Biomarkers; Cognitive loss; Complement regulators1. Introduction
Diverse homeostatic functions of central nervous system
(CNS) astrocytes support neurons in health, but the multicel-
lular changes in CNS degenerative diseases include an
increased total number of astrocytes and a greater extent of
differentiation into neurotoxic A1 inflammatory than neuro-
protective A2 ischemia-related types [1–4]. Proteins of the
classical, alternative, and lectin complement systems
provide protection against infections and toxins, regulatethor. Tel.: 1858-352-8701; Fax: 1858-246-0139.
issman@ucsd.edu
/j.dadm.2018.11.002
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).immunity especially that involving B cells, and mediate
tissue damage in myriad autoimmune and other
inflammatory diseases. Several lines of experimental
evidence suggest that complement system proteins may
mediate the capacity of type A1 astrocytes and microglia to
damage neurons [4–6]. Furthermore, astrocytes expressing
type A1 markers in areas of postmortem brain tissues
affected by neurodegenerative or neuroinflammatory
diseases have high levels of complement component 3
(C3), whereas C3 is absent from type A2 astrocytes [7].
Astrocyte-derived exosomes (ADEs) have been recov-
ered by immunoabsorption from plasma of patients with
Alzheimer’s disease (AD) and matched controls [8].imer’s Association. This is an open access article under the CC BY-NC-ND
Table 1
Demographic and cognitive characteristics of the study participants
Diagnosis
Total
number
Male/
Female
Age
(mean 1 S.D.)
MMSE,
entry
MMSE, end
(3 years)
Control 20 12/8 70.8 6 5.34 29.2 6 0.45 NA
C.N. Winston et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 11 (2019) 61-6662Plasma ADE levels of numerous classical and alternative
pathway complement effector proteins were significantly
higher in patients with AD than controls, including opso-
nizing C3b and the cellular attack complex C5b-C9 [9].
Furthermore, ADE complement levels were 6- to 50-
fold higher than corresponding values in neuron-derived
exosomes. Plasma ADE complement effector protein
levels were not significantly elevated in preclinical AD
at 5 to 12 years before cognitive losses, but some comple-
ment regulatory proteins were decreased at these early
preclinical stages and were further decreased in manifest
AD when complement effector proteins became elevated
[9].
The establishment of criteria for delineation of progres-
sive stages of preclinical AD, which correlate with an
increased risk of development of dementia proportional
to the stage of preclinical AD, has been challenging and
is still in evolution. Variables that delineate each stage of
preclinical AD have included subtle cognitive changes,
abnormal cerebrospinal fluid levels of putative pathogenic
proteins, and MRI and PET bioimaging data [10–13].
Models for predicting cognitive trajectory in mild
cognitive impairment (MCI) have proven to be especially
challenging and required application of complex multiple
domain neuropsychological testing and evaluation by
MRI of functional connectivity of CNS network
components [14–17]. Blood-based biochemical approaches
to prediction of the courses of MCI and AD have improved
in sensitivity and accuracy, but it is yet to be determined
which of a wide range of analytes are most useful for
each purpose [8,18–23].
The present study of plasma ADE complement effector
and regulatory proteins was designed to document abnor-
malities of this component of neurotoxic neuroinflamma-
tion in the common predementia condition of MCI and to
determine differences between the complement profiles of
those who would convert from MCI to dementia after 3
years and those who would remain stable at the stage of
MCI without progressive cognitive loss. A well-
characterized and previously reported series of participants
is the basis for the investigation [23]. Differences in plasma
ADE complement levels between MCI converters and
those with stable MCI were significant and were as clearly
distinct as those between patients with AD and their con-
trols.MCIS 20 13/7 68.7 6 7.76 29.0 6 0.26 28.8 6 0.33
MCIC 20 11/9 75.4 6 6.82 27.4 6 0.29 17.7 6 0.70*
AD 20 12/8 71.1 6 6.90 23.9 1 0.75* NA
Abbreviations: AD, Alzheimer’s disease; MMSE,Mini–Mental State Ex-
amination on entry into the study and at the 3-year end of the study,
mean6 SEM;MCIS, subjects with mild cognitive impairment that was sta-
ble over the 3-year study; and MCIC, subjects with mild cognitive impair-
ment on entry into the study that converted to dementia by the end of the
three-year study.
NOTE. The significance of differences in MMSE between the MCIS and
MCIC groups and between the control and AD groups was calculated with
an unpaired t-test; *P , .001. NA 5 not applicable to the control and AD
groupswhere cognitive evaluationwas conducted once on entry into the study.2. Methods
2.1. Study design, participant characterization, and blood
collection
Participants in four distinct groups were evaluated clin-
ically and by mental status testing at the time of entry into
the study and then annually for 36 months: patients with an
established diagnosis of mild-to-moderate AD (AD,
n 5 20), cognitively normal controls who were age- andgender-matched to the AD group (controls, n 5 20), pa-
tients with stable MCI that did not change during the
36 month study (MCIS, n 5 20), and patients who con-
verted within 3 years from MCI to AD dementia (MCIC,
n 5 20) (Table 1). All participants in the MCIS and
MCIC groups had been identified through the Alzheimer
Disease Cooperative Study (ADCS) Biomarker Core at
University of California, San Diego (UCSD). Participants
in the AD and control groups were from the Jewish
Home of San Francisco (JHSF). Cognitive normality of
controls was based on Mini–Mental State Examination,
level of activities of daily living, and capacity to provide
a coherent history and list of medications. Comorbidities
in the four groups were principally hypertension and type
2 diabetes mellitus and were equally distributed in the
MCIS and MCIC groups.
Mental status testing was conducted with the Mini–
Mental State Examination as described in the study by
Goetzl et al. [9]. Study patients with MCI or mild-to-
moderate dementia with high probability of AD had a Clin-
ical Dementia Rating global score of 0.5 or 1.0 according to
the NIA–Alzheimer’s Association and International Work-
ing Group-2 criteria [24]. All patients with MCI or AD
had an abnormal cerebrospinal fluid level of amyloid b-pep-
tide (Ab) 1–42, which supported their diagnosis [25].
All participants with MCI donated blood for exosome an-
alyses at the time of entry into the UCSD study and those
with AD and their controls had donated blood over the
same period of time at JHSF. Five mL of venous blood
was drawn by syringe into 0.5 mL of saline with EDTA,
incubated for 10 minutes at room temperature, and centri-
fuged for 15 minutes at 2500! g. Plasma samples were
stored in 0.25 mL aliquots at 280C.
The protocol and procedures of this study received prior
approval by the Institutional Review Boards of the Univer-
sity of California, San Francisco (for JHSF) and the
UCSD. Informed consent was obtained from each partici-
pant and often also from a family representative.
C.N. Winston et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 11 (2019) 61-66 632.2. Enrichment of plasma ADEs for extraction and ELISA
quantification of proteins
Aliquots of 0.25 mL plasma were incubated with
0.1 mL thromboplastin D (Thermo Fisher Scientific, Inc.,
Waltham, MA, USA), followed by addition of 0.15 mL
of calcium- and magnesium-free Dulbecco’s balanced salt
solution (DBS22) with protease inhibitor cocktail (Roche,
Indianapolis, IN, USA) and phosphatase inhibitor cocktail
(Thermo Fisher Scientific, Inc.; DBS11), as described
[8]. After centrifugation at 3000 ! g for 30 minutes at
4C, total exosomes were precipitated from resultant super-
natants with 126 mL per tube of ExoQuick (System Biosci-
ences, Mountain View, CA, USA) and centrifugation at
1500 ! g for 30 minutes at 4C. To enrich ADEs, total
exosomes were resuspended in 0.35 mL of DBS22 and
incubated for 60 minutes at room temperature with
1.5 mg of mouse anti-human glutamine aspartate trans-
porter (GLAST) (ACSA-1) biotinylated antibody (Miltenyi
Biotec, Inc., Auburn, CA) in 50 mL of 3% BSA (1:3.33
dilution of Blocker BSA 10% solution in DBS22; Thermo
Fisher Scientific, Inc.) per tube with mixing, followed by
addition of 10 mL of streptavidin-agarose UltraLink resin
(Thermo Fisher Scientific, Inc.) in 40 mL of 3% BSA and
incubation for 30 minutes at room temperature with mix-
ing. After centrifugation at 800! g for 10 minutes at
4C and removal of the supernate, each pellet was resus-
pended in 100 mL of cold 0.05 M glycine-HCl (pH 3.0)
by gentle mixing for 10 seconds and centrifuged at
4000! g for 10 minutes, all at 4C. Supernatants then
were transferred to clean tubes containing 25 mL of 10%
BSA and 10 mL of 1 M Tris-HCl (pH 5 8.0) and mixed
before addition of 365 mL of mammalian protein extraction
reagent (M-PER) (Thermo Fisher Scientific) with protease
and phosphatase inhibitors. Resultant 0.5 mL lysates of
ADEs were stored at 280C.
ADE proteins found to be abnormal in AD, previously
[23], were quantified by ELISA kits for human tetraspan-
ning exosome marker CD81, complement fragment C4b,
DAF (CD55) (American Research Products–Cusabio,
Waltham, MA, USA), membrane cofactor protein
(CD46), CR1 (American Research Products-Cloud-
Clone Corp., Waltham, MA), complement fragment
C3b, C1q portion of the C1 complement complex (Ab-
cam, Inc., Cambridge, MA), Bb fragment of complement
factor B (Quidel-Microvue, San Diego, CA), complement
fragment C5b and terminal complement complex C5b-C9
(Elabscience, Bethesda, MD), CD59, mannose-binding
lectin (MBL) (Ray Biotech, Inc., Norcross, GA), and
complement factor D (Thermo Fisher–Invitrogen, Lafay-
ette, CO). The mean value for all determinations of
CD81 in each assay group was set at 1.00, and relative
values of CD81 for each sample were used to normalize
their recovery.2.3. Statistical analyses
The Shapiro-Wilk test showed that data in all sets were
distributed normally. Statistical significance of differences
between means for cross-sectional groups AD and control,
MCIS and control, MCIC and MCIS, and MCIC and AD
were determined with an unpaired Student’s t-test, including
a Bonferroni correction (Prism 6; GraphPad Software, La
Jolla, CA, USA). ROC analyses were conducted to assess
the sensitivity of complement proteins (CPs) in distinguish-
ing among the subgroups of participants (Prism 6; GraphPad
Software).3. Results
The mean ADE levels of all complement effector pro-
teins for the patients with MCIC who converted to demen-
tia after 3 years were significantly higher than those for the
patients with MCIS who remained cognitively stable at the
level of MCI after 3 years (Table 1, Fig. 1). Complement
effector proteins with elevated levels in patients with
MCIC included C1q and C4b of the classical pathway, fac-
tor D, and fragment Bb of the alternative pathway and C5b,
C3b, and C5b-C9 terminal complex of both pathways.
Levels of four of the ADE complement effector proteins
show no overlap between the two groups of patients with
MCI. The exception was MBL of the lectin complement
pathway, where there was no difference between ADE
levels of the two MCI groups. Inversely, mean ADE levels
of all membrane-localized complement inhibitory proteins
for the patients with MCIC were significantly lower than
those for the patients with MCIS (Fig. 2). Significant dif-
ferences in mean ADE levels of complement effector and
inhibitory proteins separate patients with MCIC from
cognitively normal controls (Figs. 1 and 2). Similar differ-
ences between patients with AD and their controls in ADE
levels of all effector and regulatory proteins of the comple-
ment system, except MBL, were significant, as has been re-
ported for AD [9].
There were nearly universally significant differences in
ADE CP levels between participants with MCIC and
MCIS and between patients with AD and controls (Figs. 1
and 2, Table 2). Although ADE levels of seven CPs reliably
distinguished MCIS participants from controls, ADE levels
of only C4b, Bb, and CD59 significantly distinguished pa-
tients with AD from those with MCIC, who are at an early
stage of AD and converted to AD within 3 years. The CPs
that most consistently distinguished among groups were
Bb, C3b, C4b, DAF, and CD46 (Table 2). C5b, factor D,
and CR1 all failed to distinguish patients with MCIS from
controls or patients with AD from patients with MCIC
(Table 2). Overall, Bb was the best performer, and factor
D and CR1 were the least helpful.
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Fig. 1. ADE levels of complement effector proteins in cross-sectional control, MCI, and AD groups. Each point represents the value for a control or patient, and
the horizontal line in point clusters is the mean level for that group. Mean6 SEM for control, stable MCI (MCIS), MCI that converted to dementia (MCIC), and
AD patient values, respectively, are 14,560 6 1423, 8845 6 744, 51,274 6 3706, and 46,135 6 3001 pg/mL for C1q; 66,936 6 5660, 98,464 6 13,248,
698,662 6 57,983, and 162,747 6 8076 pg/mL for C4b; 1478 6 171, 1539 6 200, 5763 6 653, and 5875 6 816 pg/mL for factor D; 106,508 6 13,449,
22,503 6 2908,144,103 6 13,792, and 245,094 6 15,609 pg/mL for factor B fragment Bb; 3105 6 198, 3109 6 319, 5937 6 478, and 5238 6 244 pg/
mL for C5b; 25,571 6 2412, 7453 6 876, 64,389 6 4593, and 78,256 1 5499 pg/mL for C3b; 358 6 35.0, 523 6 47.2, 1117 6 117, and 1187 6 134 pg/
mL for C5b-C9 TCC; and 11306 131, 11226 110, 11231 116, and 11576 134 pg/mL for MBL. The significance of differences between values for controls
and AD patients, and between values for MCIS and MCIC patients, was calculated by an unpaired Student’s t-test and shown over the last two bars of each set;
*5 P, .01 and **5 P, .0001. Abbreviations: ADE, astrocyte-derived exosome; AD, Alzheimer’s disease;MCI, mild cognitive impairment;MBL, mannose-
binding lectin.
C.N. Winston et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 11 (2019) 61-66644. Discussion
Levels of ADE cargo proteins of the classical and alterna-
tive effector pathways, as well as of several distinct comple-
ment regulatory systems, differed with the nature and stage
of CNS degeneration (Figs. 1 and 2). The elevated levels of
ADE C3b and C5b-C9 terminal complex are of special inter-
est as C3b opsonization of neurons may enhance attraction
and neuronal toxicity of microglia, while the C5b-C9 com-
plex may injure neurons directly. It is not yet known whichCo
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Fig. 2. ADE levels of complement regulatory proteins in cross-sectional control, M
and the horizontal line in point clusters is the mean level for that group. Mean 6
35,166 6 3981, 11,486 6 1581, 2796 6 230, and 3825 6 499 pg/mL for DAF;
473 6 38.2, 475 6 51.9, 268 6 29.9, and 286 6 20.6 pg/mL for CR1; and 1268 6
nificance of differences between values for controls and AD patients, and between v
t-test and shown over the last two bars of each set; 1 5 P , .05, * 5 P , .01, a
Alzheimer’s disease; MCI, mild cognitive impairment; MCIC, MCI that converteprofile of ADE proteins will most significantly distinguish
stable MCI (MCIS) from that poised to convert to AD de-
mentia (MCIC) at each stage of the course. However, it is
clear that the differences between ADE levels of each pro-
tein of the classical and alternative complement pathways
were as great when comparing the MCIC group with the
MCIS group as comparing AD to controls (Figs. 1 and 2).
Diminished ADE levels of complement regulatory proteins
CD59 and DAF were found previously at the preclinicalCo
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SEM for control, MCIS, MCIC, and AD patient values, respectively, are
62.4 6 5.48, 245 6 37.3, 47.1 6 4.78, and 35.3 6 2.91 pg/mL for CD46;
84.1, 865 6 103, 584 6 60.6, and 353 6 38.5 pg/mL for CD59. The sig-
alues for MCIS andMCIC patients, was calculated by an unpaired Student’s
nd ** 5 P , .0001. Abbreviations: ADE, astrocyte-derived exosome; AD,
d to dementia; MCIS; stable MCI.
Table 2
Receiver operating characteristic (ROC) evaluation of complement protein
sensitivity in distinguishing clinical subgroups
Complement
protein
Sensitivity, % (mean 6 SEM)
MCIS vs.
control
MCIC vs.
MCIS
AD vs.
control
AD vs.
MCIC
Bb 97.8 6 0.018 100 93.0 6 0.038 85.5 6 0.059
C3b 96.3 6 0.028 100 98.0 6 0.017 65.8 6 0.088
C1q 78.3 6 0.075 100 99.3 6 0.009 __
C4b 66.3 6 0.087 99.8 6 0.004 99.0 6 0.011 100
C5b __ 89.3 6 0.052 93.8 6 0.036 __
TCC 72.6 6 0.082 92.8 6 0.039 95.0 6 0.031 __
Factor D __ 94.3 6 0.033 95.3 6 0.029 __
DAF 93.4 6 0.036 93.0 6 0.045 100 65.9 6 0.092
CD46 92.0 6 0.052 94.3 6 0.049 85.3 6 0.061 66.3 6 0.089
CD59 77.5 6 0.079 69.0 6 0.084 100 75.5 6 0.075
CR1 __ 79.3 6 0.072 83.0 6 0.064 __
Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive impair-
ment; MCIC, MCI that converted to dementia; MCIS, stable MCI.
NOTE. All values of sensitivity less than 60% are represented by dashes.
All values for MBL were lower than 60%.
C.N. Winston et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 11 (2019) 61-66 65stage of AD [9], when levels of complement effector pro-
teins were still normal, and the early appearance of abnor-
malities of similar magnitude now was detected in CD59
and DAF in the patients with MCIC as well (Fig. 2). The ca-
pacity to characterize differences in distinct sets of MCI may
prove to be most useful, as there are fewer predictive
markers for MCI conversion to AD than for staging the
course and severity of AD.
Any potential value of ADE CPs for prediction of conver-
sion and other aspects of the pathophysiology of MCI will be
dependent on considerable further validating studies of
many more patients of different age ranges, ethnicities,
and comorbidities. This is especially important as our AD
and control groups were in a long-term care facility, whereas
the participants withMCIS andMCICwere principally com-
munity based. Perhaps, these investigations will also provide
insights as to any avenues for exploitation of complement
systems as therapeutic targets inMCI, AD, or other proteino-
pathic neurodegenerative diseases.Acknowledgments
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1. Systematic review: The authors have reviewed with
PubMed reports of blood-based protein markers in
Alzheimer’s disease (AD). Inflammatory-type as-
trocytes now are recognized as neurotoxic in AD.
Our recent publication [9] reports abnormal levels of
complement proteins in plasma astrocyte-derived
exosomes (ADEs), including low levels of comple-
ment inhibitors 5-12 years before and high levels of
complement effectors at the onset of AD. Here, we
address whether ADE levels of complement proteins
in mild cognitive impairment can predict risk of
conversion to AD within 3 years.
2. Interpretation: New findings are significant eleva-
tions of ADE complement effectors and significant
depressions of complement inhibitors in patients
with mild cognitive impairment who convert to de-
mentia 3 years later.
3. Future directions: Analyses of ADE complement
proteins in a large set of patients with mild cognitive
impairment will be needed to define their usefulness
for prediction of risk and course of conversion to AD.References
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